Year: 2013
Type: article
Abstract: Copyright © 2013 Anita C. Bellail, Chunhai Hao. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Dear Readers It has been thirty-eight years since tumor necrosis fac-tor- (TNF) was isolated and found with cancer thera-peutic potential in 1975 [1]; however, all the efforts have failed in the development of TNF and its family ligands as cancer drugs [2] first due to the lethal toxicity of TNF and Fas ligand (FasL) [3,4]. In the middle 1990s, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL; Apo2 ligand, Apo2L) was identified as a mem-ber of the TNF ligand family [5,6] that can induce apop-tosis in cancer cells without the toxicity as caused by TNF and FasL [7,8], leading to renewed efforts in de-velopment of this TNF family ligand as a cancer thera-
Source: Open Journal of Apoptosis
Authors: Anita C. Bellail, Chunhai Hao
Institution: Emory University
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W2068598245